EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls

Tomoko Kato, Takaaki Murakami iD, Daisuke Yabe iD, Norio Harada iD

Journal of Diabetes Investigation · 2023-09 · 14 (9) · 1038-1040

DOI: 10.1111/jdi.14044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 25.06.2023. Verfasst von Tomoko Kato und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Heart Failure, Diabetes Mellitus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The possible mechanism of increased urinary C-peptide due to neprilysin inhibitors is investigated. Neprilysin inhibition blocks degradation of natriuretic peptides, and elicits a natriuretic and antihypertensive effect. Neprilysin inhibition might similarly block degradation of C-peptides in the kidney and thus increase the urinary C-peptide level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureDiabetes MellitusHumansAntihypertensive AgentsValsartanNeprilysinTetrazolesC-PeptideDrug CombinationsAngiotensin Receptor Antagonists

Stichwörter der Autor:innen

Angiotensin receptor-neprilysin inhibitorC-peptideNeprilysin

Substanzen

Antihypertensive AgentsValsartanNeprilysinTetrazolesC-PeptideDrug CombinationsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Center for One Medicine Innovative Translational Research, Gifu University, Gifu, Japan.

ORCID-Profile: Takaaki Murakami, Daisuke Yabe, Norio Harada

Zitieren

APA

Kato, T., Murakami, T., Yabe, D., & Harada, N. (2023). Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls. Journal of Diabetes Investigation, 14(9), 1038-1040. https://doi.org/10.1111/jdi.14044

Vancouver

Kato T, Murakami T, Yabe D, Harada N. Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls. Journal of Diabetes Investigation. 2023;14(9):1038-1040. doi:10.1111/jdi.14044

BibTeX
@article{Kato2023,
  author = {Kato, Tomoko and Murakami, Takaaki and Yabe, Daisuke and Harada, Norio},
  title = {Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls},
  journal = {Journal of Diabetes Investigation},
  year = {2023},
  volume = {14},
  number = {9},
  pages = {1038--1040},
  doi = {10.1111/jdi.14044}
}
Kostenlos starten →